Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. V. Evgenov, J. P. Stasch, M. Mino-Kenudson, E. J. Mark, E. S. Buys, L. Zou, M. Zhang, M. J. Raher, Y. Li, Y. Feng, R. C. Jones, W. Chao (Boston, United States Of America; Halle, Germany). The stimulator of soluble guanylate cyclase riociguat protects against bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2011; 38: Suppl. 55, 670

Member's Comments

No comment yet.

Related content which might interest you: Soluble guanylate cyclase stimulator riociguat prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Source: Annual Congress 2011 - Translational models of disease Year: 2011 Soluble guanylyl cyclase expression is reduced in acute lung injury Source: Eur Respir J 2006; 28: Suppl. 50, 398s Year: 2006 First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009 Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009 Down-regulation of soluble guanylyl cyclase in asthma contributes to airway hyperreactivity Source: Eur Respir J 2005; 26: Suppl. 49, 581s Year: 2005 Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 sGC activator BAY 412272 attenuates ischemia/reperfusion injury of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006 Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Source: Eur Respir J 2013; 41: 853-860 Year: 2013 Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Rho-kinase inhibitor ameliorates bleomycin-induced chronic lung injury in neonatal rats Source: Annual Congress 2011 - Issues in paediatric and neonatal intensive care Year: 2011 PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012